QBRI, Harvard Stem Cell Institute hold symposium
May 13 2019 01:08 AM
The symposium provided a platform for experts to discuss the latest research on diabetes and stem cell biology.

Qatar Biomedical Research Institute (QBRI), part of Hamad Bin Khalifa University (HBKU) and the Harvard Stem Cell Institute (HSCI) recently held an inaugural symposium in Boston, US, as part of a five-year collaborative research and training agreement.
As part of the collaborative agreement, the first project on stem cells and diabetes between the two entities has been launched. The joint project will make use of the unique integrated expertise at QBRI and HSCI and will enable researchers from the stem cell biology, diabetes, genomics and structural biology to collaborate and utilise diverse tools to discern the function of transcription factors expressed during pancreas development and play a critical role in beta-cell functionality.
The symposium provided a platform for experts to discuss the latest research and breakthroughs on diabetes and stem cell biology and concluded recently. It enabled scientists from both institutes to present their current research findings and propose specific research areas for upcoming projects.
Dr Omar El-Agnaf, executive director at QBRI, said, “Stem cell research has long been identified as a core area of study presenting many promising prospects for diabetes therapy. Our partnership with HSCI is a significant step towards diabetes and stem cell research that can have a tangible and meaningful impact on their intended segments. 
The symposium provided an opportunity for scientists to share their expertise and collectively work towards breakthroughs in the research of diabetes. 
The event yielded fruitful outcomes, and we look forward to reaping mutual benefits that will undoubtedly arise from this collaborative agreement.”
Brock Reeve, executive director, HSCI said, “Meeting with our QBRI collaborators was an excellent opportunity to hear about research developments in Qatar, and to share knowledge in a range of areas from diabetes, cardiology, and nervous system diseases to bioinformatics and early-stage research programmes. It was exciting to see our joint endeavours taking off and to discuss future projects, including clinical trials.”
In 2018, QBRI inked an important five-year agreement with HSCI that includes technical training and research in stem cell biology, which are essential for discovering viable treatments for diabetes.
QBRI staff,  working in the stem cells and diabetes field, now have the opportunity to be based in HSCI premises, where they can be trained, exchange knowledge and best practices with their Harvard peers, with the ultimate goal of translating discoveries into clinical trials and applications. 
So far, a QBRI core manager and researcher have benefited from this experience, trained and conducted research at HSCI, with more staff and students set to make use of this valuable opportunity in the future.
As a result of this partnership, QBRI investigators have access to the largest collaborative network of stem-cell researchers globally. Clinical trials arising from agreement will be conducted with QBRI stakeholders, such as Hamad Medical Corporation and Sidra Medicine.
HSCI – a network of 1,000 scientists at Harvard University and eight affiliated hospitals – is an advocate of research in stem cell biology and regenerative medicine.

There are no comments.

LEAVE A COMMENT Your email address will not be published. Required fields are marked*